Last modified: June 17, 2010
- Oxford Bioscience Partners
Companies[edit]
Web Presences[edit]
Financial Profiles[edit]
Industries[edit]
Omar Amirana | 
|
Recent Updates |
|---|
| Omar Amirana has been been added to Oxford Bioscience Partners |
| Omar Amirana is attending Physicians Interested in Entrepreneurship & Industry. |
| Omar Amirana has been featured in Join us at a Panel Event on June 29 - Physicians Interested in Entrepreneurship & Industry! . |
| Omar Amirana has been added to the Ecosystem. |
Description[edit]
Dr. Amirana is a Partner at Oxford focused on healthcare technology investing. He joined Oxford in 2005 with 15 years of industry-related experience in both large and small companies. He previously served as the Vice President of Business Development at St. Jude Medical (NYSE:STJ) focused on electrophysiology, cardiology and vascular intervention where he was also responsible for a 20 person R&D team. Dr. Amirana was formerly the CEO of Resolution Medical, a privately held cardiology company in Silicon Valley. He has helped raise over $60M in venture financing which resulted in three IPOs: EP Technologies, Cardima, and MedicaLogic/Medscape. Dr. Amirana was a co-founder of Cardima and served there for seven years as Vice President of Marketing, Business Development and Chief Technology Officer. He was also Vice President of Marketing at MedicaLogic through its IPO. Dr. Amirana has launched cardiovascular products worldwide and holds various patents. He works with Emory University and the South African government to promote life sciences entrepreneurship. He is a co-founder and the Chairman of Propel Careers, a business dedicated to fostering leadership development through internship and mentorship. He received a B.S. in Mechanical Engineering from Tufts University and an M.D. from E. Virginia Medical School.
Dr. Amirana led the firm’s investment in Nfocus Neuromedical (neurovascular implants). He serves on its board as well as the board of CardioFocus (atrial fibrillation catheter therapy), Coherex (structural heart catheter therapies), Mitralign (percutaneous valve therapy), and SmartPill (GI capsule technology). He previously served on the board of Flowmedica (targeted renal catheter therapy for AKI) and led its acquisition by Angiodynamics (Nasdaq:ANGO). He is also a Board Observer at Concentric Medical (ischemic stroke catheter therapy).